[go: up one dir, main page]

NO994904L - 4,4-disubstituerte-3,4-dihydro-2(1H)-quinazolinoner nyttig som HIV-reverstranskriptaseinhibitorer - Google Patents

4,4-disubstituerte-3,4-dihydro-2(1H)-quinazolinoner nyttig som HIV-reverstranskriptaseinhibitorer

Info

Publication number
NO994904L
NO994904L NO994904A NO994904A NO994904L NO 994904 L NO994904 L NO 994904L NO 994904 A NO994904 A NO 994904A NO 994904 A NO994904 A NO 994904A NO 994904 L NO994904 L NO 994904L
Authority
NO
Norway
Prior art keywords
disubstituted
dihydro
reverse transcriptase
transcriptase inhibitors
hiv reverse
Prior art date
Application number
NO994904A
Other languages
English (en)
Other versions
NO994904D0 (no
NO314936B1 (no
Inventor
Jeffrey W Corbett
Soo Sung Ko
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of NO994904D0 publication Critical patent/NO994904D0/no
Publication of NO994904L publication Critical patent/NO994904L/no
Publication of NO314936B1 publication Critical patent/NO314936B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19994904A 1997-04-09 1999-10-08 4,4-disubstituerte-3,4-dihydro-2(1H)-kinazolinoner, farmasöytiske sammensetninger, preparater og farmasöytiske sett til behandling av HIV-infeksjon, samt anvendelse av bestemte kinazolinoner for fremstilling av etfarmasöytisk preparat NO314936B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83854097A 1997-04-09 1997-04-09
US7132298P 1998-01-14 1998-01-14
PCT/US1998/006733 WO1998045276A2 (en) 1997-04-09 1998-04-07 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors

Publications (3)

Publication Number Publication Date
NO994904D0 NO994904D0 (no) 1999-10-08
NO994904L true NO994904L (no) 1999-12-01
NO314936B1 NO314936B1 (no) 2003-06-16

Family

ID=26752095

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19994904A NO314936B1 (no) 1997-04-09 1999-10-08 4,4-disubstituerte-3,4-dihydro-2(1H)-kinazolinoner, farmasöytiske sammensetninger, preparater og farmasöytiske sett til behandling av HIV-infeksjon, samt anvendelse av bestemte kinazolinoner for fremstilling av etfarmasöytisk preparat

Country Status (19)

Country Link
EP (1) EP0973753A2 (no)
JP (1) JP2002504095A (no)
KR (1) KR20010006146A (no)
CN (1) CN1252063A (no)
AR (1) AR012340A1 (no)
AU (1) AU734928B2 (no)
BR (1) BR9808513A (no)
CA (1) CA2284996A1 (no)
EA (1) EA001991B1 (no)
EE (1) EE9900452A (no)
HR (1) HRP980143A2 (no)
HU (1) HUP0001446A3 (no)
IL (1) IL132188A0 (no)
NO (1) NO314936B1 (no)
NZ (1) NZ500592A (no)
PL (1) PL336305A1 (no)
SK (1) SK137899A3 (no)
TW (1) TW587078B (no)
WO (1) WO1998045276A2 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509922A (ja) * 1998-03-27 2002-04-02 デュポン ファーマシューティカルズ カンパニー ４，４−二置換−３，４−ジヒドロ−２（１ｈ）−キナゾリンチオン誘導体、それらの調製法、およびｈｉｖ逆転写酵素阻害剤としてのそれらの使用
WO2000021565A1 (en) 1998-10-13 2000-04-20 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
HRP990358A2 (en) * 1998-11-19 2000-08-31 Du Pont Pharm Co Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1h)-quinazolinone
WO2000029391A1 (en) * 1998-11-19 2000-05-25 Du Pont Pharmaceuticals Company Process for the preparation of quinazolinones
US6175009B1 (en) 1999-11-18 2001-01-16 Dupont Pharmaceuticals Company Process for the preparation of quinazolinones
ES2249309T3 (es) 1999-11-23 2006-04-01 Smithkline Beecham Corp Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
AU2001249161A1 (en) * 2000-03-23 2001-10-03 Bristol-Myers Squibb Pharma Company Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors
US6555686B2 (en) * 2000-03-23 2003-04-29 Bristol-Myers Squibb Pharma Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
ZA200300255B (en) 2000-07-20 2004-09-28 Bristol Myers Squibb Pharma Co Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors.
US6596729B2 (en) 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
AU2003295940A1 (en) * 2002-12-16 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
WO2005037095A1 (en) 2003-10-14 2005-04-28 Pelikan Technologies, Inc. Method and apparatus for a variable user interface
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc METHOD AND DEVICE FOR A LIQUID DETECTION DEVICE
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
CN102060786A (zh) * 2011-01-20 2011-05-18 天津大学 4-(取代-1,3-二炔基)-4-(三氟甲基)-3,4-二氢取代喹唑啉-2-酮类化合物及其制备方法和应用
AP2013007166A0 (en) * 2011-04-06 2013-10-31 Univ Paris Descartes Inst De Rech Pour Le Dev Ird Pharmaceutical compositions for preventing and/or treating an HIV disease in humans
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
CN105209467B (zh) 2013-05-27 2018-06-08 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
CA2912986A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
PL3004112T3 (pl) 2013-05-28 2018-02-28 Novartis Ag Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
AU2014351413B2 (en) 2013-11-21 2017-06-01 Novartis Ag Pyrrolopyrrolone derivatives and their use as BET inhibitors
CN116745269A (zh) * 2020-08-27 2023-09-12 默沙东有限责任公司 用于治疗hiv的作为选择性细胞毒性剂的二氢喹唑啉-2-酮衍生物
AR133187A1 (es) * 2023-07-07 2025-09-03 Merck Sharp & Dohme Llc Derivados de tetrahidroquinazolina como agentes citotóxicos selectivos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
CZ272494A3 (en) * 1992-05-07 1995-10-18 Merck & Co Inc Quinazoline derivatives, synergetic combinations of said derivatives with other matters against hiv and a pharmaceutical preparation containing the quinazolidine derivatives or the synergetic combinations
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4320347A1 (de) * 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
AU1046895A (en) * 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5434152A (en) * 1993-11-08 1995-07-18 Merck & Co., Inc. Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone

Also Published As

Publication number Publication date
EA199900907A1 (ru) 2000-04-24
EA001991B1 (ru) 2001-10-22
EE9900452A (et) 2000-04-17
TW587078B (en) 2004-05-11
NZ500592A (en) 2001-09-28
AR012340A1 (es) 2000-10-18
CA2284996A1 (en) 1998-10-15
HUP0001446A2 (hu) 2001-05-28
PL336305A1 (en) 2000-06-19
AU734928B2 (en) 2001-06-28
AU6796098A (en) 1998-10-30
WO1998045276A2 (en) 1998-10-15
JP2002504095A (ja) 2002-02-05
HUP0001446A3 (en) 2001-11-28
NO994904D0 (no) 1999-10-08
NO314936B1 (no) 2003-06-16
BR9808513A (pt) 2000-05-23
CN1252063A (zh) 2000-05-03
IL132188A0 (en) 2001-03-19
HRP980143A2 (en) 1999-02-28
KR20010006146A (ko) 2001-01-26
EP0973753A2 (en) 2000-01-26
SK137899A3 (en) 2000-05-16
WO1998045276A3 (en) 1999-01-14

Similar Documents

Publication Publication Date Title
NO994904L (no) 4,4-disubstituerte-3,4-dihydro-2(1H)-quinazolinoner nyttig som HIV-reverstranskriptaseinhibitorer
DK0945443T3 (da) HIV-hæmmende pyrimidinderivater
DK1002795T3 (da) HIV-replikationsinhiberende pyrimidiner
DK1114032T3 (da) 4-aminosubstituerede-2-substituerede-1,2,3,4-tetrahydroquinoliner som CETB-inhibitorer
NO20012701D0 (no) Aryl- og heterosyklylsubstituerte pyrimidinderivater som antikoagulanter
LTPA2012008I1 (lt) Pirimidino dariniai, slopinantys živ
FI20040309A7 (fi) Bentsoksatsinonit HIV-käänteistranskriptaasin estäjinä
NO20022557D0 (no) 2,4-diaminopyrimidinforbindelser nyttige som immunosuppreserende midler
FI953954L (fi) HIV:n käänteistranskriptaasin inhibiittoreita
ID24361A (id) Alat penyampur
ATE303388T1 (de) Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate
DK1023268T3 (da) Isoquinoliner som urokinaseinhibitorer.
NO981846D0 (no) Beskyttelsesbrille, spesielt arbeidsbeskyttelsesbrille
AU3199099A (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
AU4698399A (en) 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
NO996244D0 (no) Pyrrolidinkarboksylsyrederivater som endotelinantagonister
DK0915076T3 (da) Fremgangsmåde til fremstilling af trans-(R,R)-actinol
ID20174A (id) Alat pengungkit
DE59910200D1 (de) Kühlbares Bauteil
AU2003263838A1 (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazoliniones useful as hiv reverse transcriptase inhibitors
ZA982339B (en) 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors.
DK0882044T3 (da) 1,4-dihydropyridinforbindelser som bradykinin-antagonister
AU5588400A (en) 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
DK0966464T3 (da) Substituerede 2,4-diaminopyrimidiner
KR960005287U (ko) 건축, 토목용 비계 설치구

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees